Announcements Trials
Browse Landscape

Phase

Phase 1 1

Status

Terminated 1

Sponsor Class

INDUSTRY 1

Study Type

Interventional 1

Sponsor

Cancer Type

Sarcoma 1Other hematologic neoplasm 1Lymphoid 1Gastrointestinal 1

Conditions

Colorectal Neoplasms 17Neoplasms 5Neoplasm Metastasis 5Colonic Neoplasms 4Stomach Neoplasms 3Ovarian Neoplasms 3Lung Neoplasms 3Gastrointestinal Neoplasms 3Rectal Neoplasms 2Lymphoma, Non-Hodgkin 2Leukemia, Myeloid, Acute 2Carcinoma, Renal Cell 2Carcinoma, Non-Small-Cell Lung 2Breast Neoplasms 2Uterine Cervical Neoplasms 1Urinary Bladder Neoplasms 1Unresectable Metastatic Colorectal Cancer 1Triple Negative Breast Neoplasms 1Squamous Cell Carcinoma of Head and Neck 1Solid Tumors 1Sarcoma 1Prostatic Neoplasms 1Pancreatic Neoplasms 1Melanoma 1Lymphoma, Large B-Cell, Diffuse 1Leukemia, Lymphocytic, Chronic, B-Cell 1Kidney Neoplasms 1Hematologic Neoplasms 1Head and Neck Neoplasms 1Gastroesophageal Adenocarcinoma 1

Interventions

Gemcitabine 3Docetaxel 3belinostat 2Fluorouracil 2Bevacizumab 2venetoclax 1toripalimab 1tanespimycin 1ivosidenib 1itacitinib 1durvalumab 1capivasertib 1birinapant 1baricitinib 1Zoledronic Acid 1Thalidomide 1Taxes 1Radiotherapy 1Paclitaxel 1Medicare Part B 1Leucovorin 1Irinotecan 1Immunoglobulin G 1INCB039110 1IFL protocol 1Filgrastim 1Disulfides 1Cisplatin 1Chemotherapy, Adjuvant 1Celecoxib 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Phase 1 × Chondrosarcoma × IFL protocol × Clear all
NCT04553692 2025-03-28

Phase 1a/1b Study of Aplitabart (IGM-8444) Alone or in Combination in Participants with Relapsed, Refractory, or Newly Diagnosed Cancers

IGM Biosciences, Inc.

Phase 1 Terminated
272 enrolled
GastrointestinalLymphoidOther hematologic neoplasmSarcoma

Chondrosarcoma, Lymphoma, Non-Hodgkin, Neoplasm Metastasis, Sarcoma, Colorectal Neoplasms, Leukemia, Lymphocytic, Chronic, B-Cell, Leukemia, Myeloid, Acute

Data powered by HemOnc (CC BY 4.0) Colophon âš¡